ProCE Banner Activity

Pharmacy Perspectives: Key Takeaways From the 2023 Atrial Fibrillation Guideline Updates

Clinical Thought

Learn strategies as outlined in the updated guidelines to better manage patients with atrial fibrillation, including special considerations for those in specific at-risk populations (eg, obesity, frailty) and how to implement shared decision-making using validated tools, for pharmacists involved in the multidisciplinary care of these individuals.

Released: June 13, 2024

Expiration: June 12, 2025

Share

Faculty

Craig I. Coleman

Craig I. Coleman, PharmD, FASHP, FACC

Professor, University of Connecticut
Director, Evidence-Based Practice Center
Hartford Hospital
Hartford, Connecticut

Provided by

Provided by Clinical Care Options, LLC in partnership with ProCE, LLC.

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Partners

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

Craig I. Coleman, PharmD, FASHP, FACC

Professor, University of Connecticut
Director, Evidence-Based Practice Center
Hartford Hospital
Hartford, Connecticut

Craig I. Coleman, PharmD, FASHP, FACC: consultant/advisor/speaker: AstraZeneca, Bayer AG, F2G, Janssen Scientific Affairs.